<DOC>
	<DOCNO>NCT00475553</DOCNO>
	<brief_summary>The purpose research study evaluate best way manage breakthrough spot bleed extend use regimen NuvaRing® . Ease use acceptability flexible regimen NuvaRing® also evaluate . A comparison cyclic mood symptom , pelvic pain , headache make standard 21/7 regimen extend regimen .</brief_summary>
	<brief_title>Management Breakthrough Bleeding During Extended Therapy Use With NuvaRing®</brief_title>
	<detailed_description>Hormonal contraception undergo change away 21/7 day regimen woman utilize combination estrogen progestin therapy 21 day follow 7 day hormone-free interval ( HFI ) . It well document woman may experience high incidence mood change , headache cramp begin prior 7 day HFI . By reduce HFI extend active combination contraceptive therapy , hop woman experience great satisfaction contraceptive regimen experience few negative side effect associate HFI . The common reason discontinuation extend contraception regimen irregular bleeding . The purpose research study evaluate best way manage breakthrough spot bleeding . Ease use acceptability flexible regimen NuvaRing also evaluate . A comparison cyclic mood symptom , pelvic pain , headache make standard 21/7 regimen extend regimen . The contraceptive ring use study contain estrogen ( ethinyl estradiol ) progestin ( etonogestrel ) . These synthetic ( man-made ) hormone . The amount ethinyl estrogen release bloodstream day 120mcg amount etonogestrel 150mcg . The NuvaRing® , Organon , FDA approve contraception , approve use extend regimen . Therefore use study consider investigational .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Age 1845 year age Currently utilize combination estrogen/progestin contraception period least 2 month 1 month previously use progestin pill . Body Mass Index ( BMI ) 38 great Anyone use hormonal contraception due contraindication Anyone smoke &gt; 10 cigarette per day 35 year old old smoke cigarettes Anyone take antiretroviral therapy ( due many drug interaction ) Women use estrogencontaining product herbal product contain phytoestrogens Known suspect pregnancy , desire pregnancy next year Additionally , NuvaRing® use woman currently follow condition : Thrombophlebitis A past history deep vein thrombophlebitis thromboembolic disorder Cerebral vascular coronary artery disease ( current history ) Valvular heart disease thrombogenic complication Severe hypertension Diabetes vascular involvement Headaches focal neurological symptom Major surgery patient prolonged immobilization Known suspect carcinoma breast personal history breast cancer Carcinoma endometrium know suspected estrogen dependent neoplasia Undiagnosed abnormal genital bleeding Cholestatic jaundice pregnancy jaundice prior hormonal contraceptive use Hepatic tumor ( benign malignant ) active live disease Hypersensitivity components NuvaRing®</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>spot</keyword>
	<keyword>PMS</keyword>
	<keyword>nuvaring</keyword>
	<keyword>birth control</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>headache</keyword>
	<keyword>mood swing</keyword>
	<keyword>continuous use</keyword>
</DOC>